IL5 and interstitial lung disease: Remarkably, the interstitial lung disease showed near‐complete reversibility following targeted inhibition of the IL‐5 pathway with mepolizumab, highlighting the potential role of Th2‐driven eosinophilic inflammation in the pathogenesis of certain forms of interstitial lung disease.